Cancer Communications

Papers
(The median citation count of Cancer Communications is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Kindlin‐1 drives early steps of breast cancer metastasis563
380
347
Treatment of Metastatic Cancer by Conferring Immunogenicity to the Apoptotic Bodies of the Primary Tumor284
Single‐cell transcriptomics and epigenomics point to CD58‐CD2 interaction in controlling primary melanoma growth and immunity272
Correction to “Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges”254
Nine‐fold variation of risk of advanced colorectal neoplasms according to smoking and polygenic risk score: Results from a cross‐sectional study in a large screening colonoscopy cohort233
Issue Information211
Loss of CDKN1B induces an age‐related clonal hematopoietic disorder via Notch2 activity dysregulation207
Fascin lysine 471 acetylation cooperates with serine 39 phosphorylation to inhibit actin‐bundling activity and tumor metastasis in esophageal squamous cell carcinoma165
Issue Information159
Issue Information158
Defining and tracing subtypes of patient‐derived xenograft models in pancreatic ductal adenocarcinoma149
Combined local therapy and CAR‐GPC3 T‐cell therapy in advanced hepatocellular carcinoma: a proof‐of‐concept treatment strategy146
Long‐term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study144
Dysregulated proline metabolism exacerbates HCC metastasis via EPRS1-mediated mRNA translation141
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update133
Current status and perspectives of esophageal cancer: a comprehensive review131
Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives127
Validation of different personalized risk models of chemotherapy‐induced nausea and vomiting: results of a randomized, double‐blind, phase III trial of fosaprepitant for cancer patients treated with h122
Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial113
Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II‐III gastric cancer111
102
101
Oral transforming growth factor‐beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti‐tumor immunity95
EXPRESSION OF CONCERN: Discovery of a Novel Viroid‐Like Circular RNA in Colorectal Cancer94
Comparative single‐cell analysis of esophageal cancer subtypes reveals tumor microenvironment distinctions explaining varied immunotherapy responses94
Partial hepatectomy versus interventional treatment in patients with hepatitis B virus‐related hepatocellular carcinoma and clinically significant portal hypertension: a randomized comparative clinica93
Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5‐year update of 78
Impact of pre‐existing cardiometabolic diseases on metastatic cancer stage at diagnosis: a prospective multinational cohort study69
Issue Information67
Development and validation of an artificial intelligence model for predicting post‐transplant hepatocellular cancer recurrence67
p38γ and p38δ as biomarkers in the interplay of colon cancer and inflammatory bowel diseases65
Nasopharyngeal carcinoma treatment paradigm after HK0501 – a potential way forward65
Single‐cell transcriptomics provides insights into the origin and immune microenvironment of cervical precancerous lesions65
A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer64
Issue Information61
Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer60
N 6 ‐methyladenosine‐regulated exosome biogenesis orchestrates an immunosuppressive pre‐metastatic niche in gastric cancer peritoneal metastas60
First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial60
Targeting IL‐17A to manage immunotherapy‐induced toxicity in melanoma59
FOXO1 or not FOXO1: that is the question59
A strong internal promoter drives massive expression of YEATS‐domain devoid MLLT3 transcripts in HSC and most lethal AML58
Acquired RD3 loss regulates immune surveillance in high‐risk and therapy defying progressive neuroblastoma57
Association of previously irradiated stable brain metastases with outcomes of atezolizumab‐treated non‐small cell lung cancer: A pooled analysis of individual patient data from three randomized trials56
Cover Image, Volume 45, Issue 656
Issue Information54
Impact of small molecule‐mediated inhibition of ammonia detoxification on lung malignancies and liver metabolism53
Antitumoral effects of cannabis in Notch1 ‐mutated T‐cell acute lymphoblastic leukemia53
Ubiquitination in cancer: mechanisms and therapeutic opportunities53
Comprehensive DSRCT multi‐omics analyses unveil CACNA2D2 as a diagnostic hallmark and super‐enhancer‐driven EWSR1::WT1 signature gene51
Novel molecular mechanisms of immune evasion in hepatocellular carcinoma: NSUN2‐mediated increase of SOAT2 RNA methylation50
First-Line Tislelizumab Combined with Bevacizumab and CAPOX for Metastatic Gastroesophageal Adenocarcinoma with Low Programmed Death-Ligand 1 Expression49
Harnessing chimeric antigen receptor macrophages against solid tumors49
Incidence of and survival with bone and soft tissue sarcoma: A nation‐wide study over four decades47
m 6 A‐modified EHD1 controls PD‐L1 endosomal trafficking to modulate immune evasion and immunotherapy responses in lung adenocarcinoma46
Enhanced selection of people for lung cancer screening using AHRR (cg05575921) or F2RL3 (cg03636183) methy46
Transcriptomic analyses of localized prostate cancers of East Asian and North American men reveal race‐specific luminal‐basal and microenvironmental differences45
Correction to “Circulating tumor cells share RNA modules with early embryo trophectoderm and with metastatic cancer”45
Low household income and income volatility increase risk of lung cancer: A nationwide retrospective cohort study44
Issue Information43
An HGF‐dependent positive feedback loop between bladder cancer cells and fibroblasts mediates lymphangiogenesis and lymphatic metastasis41
Development of antibody‐drug conjugates in cancer: Overview and prospects41
Breast cancer: an up‐to‐date review and future perspectives40
4‐1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4‐1BB agonists40
Neuroinflammation drives apathy in cancer cachexia39
Inhibition of mTOR attenuates the initiation and progression of BRCA1 ‐associated mammary tumors39
Vebreltinib for Previously Treated Astrocytoma, IDH -Mutant, Grade 4, and Glioblastoma, IDH Wild-Type with39
Long‐term antibiotic use and risk of hepatocellular carcinoma later in life: a nationwide cohort study of 9.8 million participants38
Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract38
Genomic information of children with malignant brain tumors for the prediction of length of hospitalization38
circCAPRIN1 interacts with STAT2 to promote tumor progression and lipid synthesis via upregulating ACC1 expression in colorectal cancer38
Breaking barriers: The cGAS‐STING pathway as a novel frontier in cancer immunotherapy37
Spatial metabolomics for evaluating response to neoadjuvant therapy in non‐small cell lung cancer patients37
36
N‐acetyltransferase 10 promotes colon cancer progression by inhibiting ferroptosis through N4‐acetylation and stabilization of ferroptosis suppressor protein 1 (FSP1) mRNA36
Issue Information36
Knowing nodal Rouviére: the power of human intelligence in toxicity reduction35
Single‐cell and bulk transcriptomics identifies a tumor‐specific CD36 + cancer‐associated fibroblast subpopulation in colorectal cancer35
Combination of photodynamic therapy and stimulator of interferon genes (STING) agonist inhibits colorectal tumor growth and recurrence35
Cover Image, Volume 44, Issue 435
Issue Information35
Pancreatic cancer survival trends in the US from 2001 to 2014: a CONCORD‐3 study34
Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium34
Issue Information34
Enhancement of CAR‐T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins32
Breaking barriers: Smart vaccine platforms for cancer immunomodulation32
Preoperative Chemoradiotherapy versus Chemotherapy for Locally Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma: A Phase III Randomized Controlled Trial from China32
DNA methylation signature predicts cancer response to demethylation agents from profiling diverse cancer cell lines31
Tumor microenvironment signaling and therapeutics in cancer progression30
Effect of neutrophils on tumor immunity and immunotherapy resistance with underlying mechanisms30
Lipid metabolism reprograming by SREBP1‐PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy30
Galectin 3‐binding protein (LGALS3BP) depletion attenuates hepatic fibrosis by reducing transforming growth factor‐β1 (TGF‐β1) availability and inhibits hepatocarcinogenesis30
The E3 ubiquitin ligase HUWE1 acts through the N‐Myc‐DLL1‐NOTCH1 signaling axis to suppress glioblastoma progression29
Harnessing the Power of CAR-NK Cells for Solid Tumors: Challenges, Innovations, and Future Frontiers in Immunotherapy29
The Ly6g high Neutrophil Subset Dictates Breast Cancer Lung Metastasis via CD8 + T Cell Death29
Enhancing sensitivity of triple‐negative breast cancer to DNA‐damaging therapy through chemical inhibition of the m6A methyltransferase METTL329
Targeting ferroptosis resistance resensitizes metastatic HR + HER2 breast cancer cells to palboc28
Issue Information27
27
TOPK Suppresses the CD8 + T Cell Antitumor Immunity via Modulation of IRF5 Expression26
Beyond success: unveiling the hidden potential of radiotherapy and immunotherapy in solid tumors25
A single measurement of fecal hemoglobin concentration outperforms polygenic risk score in colorectal cancer risk assessment24
Advanced precision modeling reveals divergent responses of hepatocellular carcinoma to combinatorial immunotherapy24
Camrelizumab Plus Nab-paclitaxel in Patients with Previously Treated Advanced Urothelial Carcinoma: A Multicenter Phase II Study23
Single‐cell‐eQTL mapping in circulating immune cells reveals genetic regulation of response‐associated networks in lung cancer immunotherapy23
Leptin‐mediated suppression of lipoprotein lipase cleavage enhances lipid uptake and facilitates lymph node metastasis in gastric cancer23
Cover Image, Volume 43, Issue 623
Ex vivo STAT3 phosphorylation in circulating immune cells: a novel biomarker for early cancer diagnosis and response to anti‐PD‐1 therapy23
The regulatory roles and clinical significance of glycolysis in tumor22
Targeting N4‐acetylcytidine suppresses hepatocellular carcinoma progression by repressing eEF2‐mediated HMGB2 mRNA translation22
Tumor‐derived insulin‐like growth factor‐binding protein‐1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors22
In vivo intratumoral heterogeneity in a dish: scalable forebrain organoid models of embryonal brain tumors for high‐throughput personalized drug discovery21
HMGB3 promotes brain metastasis of lung adenocarcinoma by recruiting SSBP1 for nuclear translocation to remodel mitochondrial metabolism21
21
Multiplexed CRISPR/Cas9 Editing of Tumor Suppressor Genes in the Mouse Endometrium Recapitulates High-Risk Endometrial Carcinoma20
Perivascular localized cells commit erythropoiesis in PDGF‐B‐expressing solid tumors20
Single‐cell atlas reveals a distinct immune profile fostered by T cell‐B cell crosstalk in triple negative breast cancer20
Lysosomal TMEM9‐LAMTOR4‐controlled mTOR signaling integrity is required for mammary tumorigenesis20
Real‐world outcomes of niraparib treatment in patients with ovarian cancer: a multicenter non‐interventional study in China20
Concurrent chemoradiotherapyof different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma: A randomized, multicenter, phase III clinica19
Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients19
TIMELESS Promotes LUAD Growth via Suppressing Transferrin-Mediated Ferroptosis and Reprograms the Tumor Microenvironment against Anti-PD-1 Immunotherapy19
The SARS‐CoV‐2 spike protein induces lung cancer migration and invasion in a TLR2‐dependent manner19
NHE7 upregulation potentiates the uptake of small extracellular vesicles by enhancing maturation of macropinosomes in hepatocellular carcinoma18
RNA m 1 A methyltransferase TRMT61A promotes colorectal tumorigenesis by enhancing ONECUT2 mRNA stabil18
Dlk1 is a novel adrenocortical stem/progenitor cell marker that predicts malignancy in adrenocortical carcinoma18
Transient and DNA‐free in vivo CRISPR/Cas9 genome editing for flexible modeling of endometrial carcinogenesis17
Issue Information17
Targeted STAT1 therapy for LZTR1‐driven peripheral nerve sheath tumor17
Diagnostic value of genetic mutation analysis and mutation profiling of cell‐free DNA in intraocular fluid for vitreoretinal lymphoma17
Efficacy, safety and biomarkers of SG001 for patients with previously treated recurrent or metastatic cervical cancer: an open‐label, multicenter, phase Ib trial17
Discovery of a novel viroid‐like circular RNA in colorectal cancer17
The Roles of Protein S -Palmitoylation in Cancers: From Dynamic Modulation to Therapeutic Potential16
Cancer diagnosis is one quarter lower than the expected cancer incidence in the first year of COVID‐19 pandemic in Germany: A retrospective register‐based cohort study16
Lung cancer risk score for ever and never smokers in China16
Smoking, smoking cessation, and survival after cancer diagnosis in 128,423 patients across cancer types16
Unraveling the routes to distant metastases in colorectal cancer: Tumor deposits and lymph node metastases as the gateway16
Methionine restriction sensitizes cancer cells to immunotherapy15
A phase II study on Mefatinib as first‐line treatment of patients with advanced non‐small‐cell lung cancer harboring uncommon EGFR mutations15
Engineering heavy chain antibody‐drug conjugates against solid tumors for a one‐shot kill15
Exciting progress in targeted therapy innovation for unresectable stage III EGFR ‐mutated NSCLC: the phase III LAURA study15
Combining methylated SEPTIN9 and RNF180 plasma markers for diagnosis and early detection of gastric cancer15
Combating cancer immunotherapy resistance: a nano‐medicine perspective14
Blockage of EGFR/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastoma14
Issue Information14
14
Cover Image, Volume 43, Issue 1214
Cellular senescence and metabolic reprogramming: Unraveling the intricate crosstalk in the immunosuppressive tumor microenvironment14
14
Issue Information14
Vascular smooth muscle cell plasticity in the tumor microenvironment13
Prediction of major adverse cardiac events is the first critical task in the management of immune checkpoint inhibitor‐associated myocarditis13
Cover Image, Volume 43, Issue 913
Issue Information13
Dynamic epi‐transcriptomic landscape mapping with disease progression in estrogen receptor‐positive breast cancer13
Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)‐T therapy has potential to reduce escape from single‐target CAR‐T with no more hematotoxicity13
Lymphatic metastasis in non‐small cell lung cancer: recent discoveries and novel therapeutic targets12
CD24 is a promising immunotherapeutic target for enhancing efficacy of third‐generation EGFR‐TKIs on EGFR‐mutated lung cancer12
Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2‐positive gastric cancer12
Cover Image, Volume 42, Issue 612
MFSD2A potentiates gastric cancer response to anti‐PD‐1 immunotherapy by reprogramming the tumor microenvironment to activate T cell response12
Plasma small‐extracellular vesicles enriched in miR‐122‐5p promote disease aggressiveness in pediatric anaplastic large‐cell lymphoma12
Transcription factor ETV4 promotes the development of hepatocellular carcinoma by driving hepatic TNF‐α signaling12
Nicotinamide N‐methyltransferase negatively regulates metastasis‐promoting property of cancer‐associated fibroblasts in lung adenocarcinoma11
WTAP-Mediated Glutaminase Splicing Bias Suppresses Ferroptosis in Hepatocellular Carcinoma11
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 202311
Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple‐negative breast cancer to immune checkpoint inhibitors11
Stereotactic body radiotherapy plus cadonilimab (PD‐1/CTLA‐4 bispecific antibody) as third‐line or beyond therapy for refractory solid tumors: A phase 1b study11
Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non‐small‐cell lung cancer characterizes the features of response to PD‐1 blockade plus chemotherapy10
Intratumoral CD103 + CD8 + T cells predict response to neoadjuvant chemoimmunotherapy in advanced 10
NAT10 regulates tumor progression and immune microenvironment in pancreatic ductal adenocarcinoma via the N4‐acetylated LAMB3‐mediated FAK/ERK pathway10
Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial10
Targeting MAN1B1 potently enhances bladder cancer antitumor immunity via deglycosylation of CD4710
Transcriptome‐wide association analysis identified candidate susceptibility genes for nasopharyngeal carcinoma10
Training the synergy between Bacillus Calmette‐Guérin and immune checkpoint‐blocking antibodies in bladder cancer10
Identification of telomere maintenance gene variations related to lung adenocarcinoma risk by genome‐wide association and whole genome sequencing analyses10
Issue Information10
Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation‐based therapy10
KRAS ‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer10
Tumor derived cell‐free nucleic acid upregulates programmed death‐ligand 1 expression in neutrophil via intracellular Toll‐like receptor signaling10
Effectiveness of Lung Cancer Screening by Sex and Tumor Histology: Extended, Pooled Analysis of the ITALUNG and LUSI Trials, with Comparison to Findings in the NLST10
Semaglutide impairs bioavailability of alectinib: a note of warning based on a cross‐over pharmacokinetic drug‐drug interaction study9
Vitamin D 3 for reducing mortality from cancer and other outcomes before, during and beyond the COVID‐19 pandemic: A plea for harvesting low‐hanging 9
Survival trends of patients with non‐metastatic gastric adenocarcinoma in the US and European countries: the impact of decreasing resection rates9
Simvastatin overcomes the pPCK1‐pLDHA‐SPRINGlac axis‐mediated ferroptosis and chemo‐immunotherapy resistance in AKT‐hyperactivated intrahepatic cholangiocarcinoma9
Issue Information9
Cover Image, Volume 42, Issue 89
Dietary intake of advanced glycation endproducts (AGEs) and cancer risk across more than 20 anatomical sites: A multinational cohort study9
Cover Image, Volume 43, Issue 119
Issue Information8
Converting “cold” to “hot”: epigenetics strategies to improve immune therapy effect by regulating tumor‐associated immune suppressive cells8
Serologic status and safety of inactivated Covid‐19 vaccine for hepatocellular carcinoma patients with cirrhosis after curative liver resection8
The interplay between natural killer cells and pancreatic stellate cells in pancreatic ductal adenocarcinoma8
8
Unveiling quality of clinical trial in China: from concern to confirmation8
A practical overview and statistical analysis of interval‐censored data in cancer8
Cancer‐associated fibroblast‐derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib8
8
A serum exosomal microRNA‐based artificial intelligence diagnostic model for highly accurate detection of hepatocellular carcinoma8
Cover Image, Volume 42, Issue 68
Endopharyngeal Ultrasound-Guided Transpharyngeal Needle Aspiration for Confirming Retropharyngeal Lymph Nodes’ Metastasis among Nasopharyngeal Carcinoma Patients8
Neutrophils in cancer: At the crucial crossroads of anti‐tumor and pro‐tumor8
Parkin deficiency promotes colorectal tumorigenesis and progression through RIPK3‐dependent necroptotic inflammation8
Helicobacter pylori CagA elevates FTO to induce gastric cancer progression via a “hit‐and‐run” paradigm8
Non‐small cell lung cancer in China7
SALIRI‐based (raltitrexed plus irinotecan) therapy as a second‐line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non‐interventional, registry study7
Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors7
Issue Information7
Cytosolic TGM2 promotes malignant progression in gastric cancer by suppressing the TRIM21‐mediated ubiquitination/degradation of STAT1 in a GTP binding‐dependent modality7
Dysfunction of dendritic cells in tumor microenvironment and immunotherapy7
Evaluation of exposure‐response‐safety relationship of model‐informed low‐dose 500 mg abiraterone acetate in prostate cancer patients7
A non‐metabolic function of hexokinase 2 in small cell lung cancer: promotes cancer cell stemness by increasing USP11‐mediated CD133 stability7
Single‐cell transcriptomic analysis uncovers intratumoral heterogeneity and drug‐tolerant persister in ALK ‐rearranged lung adenocarcinoma7
miR‐99a‐5p modulates doxorubicin resistance via the COX‐2/ABCG2 axis in triple‐negative breast cancer: from the discovery to in vivo studies7
Dual inhibition of sirtuins 1 and 2: reprogramming metabolic energy dynamics in chronic myeloid leukemia as an immunogenic anticancer strategy7
Fusobacterium is toxic for head and neck squamous cell carcinoma and its presence may determine a better prognosis7
Enhancing antitumor immunity through the combination of cholesterolized TLR7 agonist liposomes and radiotherapy: a role for IL‐1β and the inflammasome pathway7
Issue Information7
Issue Information6
Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies6
NAT10‐mediated ac 4 C‐modified ANKZF1 promotes tumor progression and lymphangiogenesis in clear‐cell renal cell carcinoma by attenuating YWHAE‐driven6
Copper in cancer: friend or foe? Metabolism, dysregulation, and therapeutic opportunities6
Aerobic glycolysis promotes tumor immune evasion and tumor cell stemness through the noncanonical function of hexokinase 26
6
Anbenitamab in combination with chemotherapy in patients with HER2‐positive gastric or gastroesophageal junction carcinoma who failed previous therapy containing trastuzumab: a multicenter, phase II s6
Activation mechanisms of clinically distinct B‐Raf V600E and V600K mutants6
Exposure of benzo[a]pyrene induces HCC exosome‐circular RNA to activate lung fibroblasts and trigger organotropic metastasis6
Beyond the Gut: The intratumoral microbiome's influence on tumorigenesis and treatment response6
Cytokine‐ and chemokine‐induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy6
Targeting SPHK1 in macrophages remodels the tumor microenvironment and enhances anti‐PD‐1 immunotherapy efficacy in colorectal cancer liver metastasis6
6
Immunosuppressive JAG2 + tumor‐associated neutrophils hamper PD‐1 blockade response in ovarian cancer by mediating the differentiation of effector re6
“Find Me” and “Eat Me” signals: tools to drive phagocytic processes for modulating antitumor immunity6
Targeted reactivation of the novel tumor suppressor DAPK1, an upstream regulator of p53, in high‐grade serous ovarian cancer by mRNA liposomes reduces viability and enhances drug sensitivity in precli6
6
Single‐cell multi‐omics reveals tumor microenvironment factors underlying poor immunotherapy responses in ALK‐positive lung cancer6
Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions6
6
6
Cover Image, Volume 45, Issue 126
Cover Image, Volume 45, Issue 15
Issue Information5
Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR ‐mutated, advanced non‐small cell lung cancer: data fro5
Weakened humoral immune responses of inactivated SARS‐CoV‐2 vaccines in patients with solid tumors5
Older adults living with gastrointestinal cancers in 20215
Rescue of p53 functions by in vitro‐transcribed mRNA impedes the growth of high‐grade serous ovarian cancer5
Issue Information5
Unraveling the effects of screening colonoscopy on colorectal cancer early detection and prevention: the NordICC trial revisited5
Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor5
0.077763080596924